mva62b
Vaccineexperimental
Clinical trial activity
5 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2009 (NCT00820846)
Timeline
Indications
Studied for
Mechanism of action
- Human immunodeficiency virusImmunity, active
Human immunodeficiency virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- mva62b
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02852005 | Phase 1 | Jan 1, 2017 | National Institute of Allergy and Infectious Diseases (NIAID), University of Alabama, Birmingham |
| NCT01909414 | Phase 1 | Jul 24, 2013 | National Institute of Allergy and Infectious Diseases (NIAID), University of Massachusetts |
| NCT01571960 | Phase 1 | Apr 1, 2012 | City of San Francisco, GeoVax, Inc., National Institute of Allergy and Infectious Diseases (NIAID), University of Rochester |
| NCT01378156 | Phase 1 | Jun 1, 2010 | AIDS Research Alliance, AIDS Research Consortium of Atlanta, GeoVax, Inc., University of Alabama, Birmingham |
| NCT00820846 | Phase 2 | Jan 1, 2009 | National Institute of Allergy and Infectious Diseases (NIAID), University of Alabama, Birmingham |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 4 | 4 | 2 | 2009 |
| University of Alabama, Birmingham | Academic/Hospital | 3 | 0 | 2 | 2009 |
| GeoVax, Inc. | For profit | 2 | 1 | 1 | 2010 |
| AIDS Research Alliance | Academic/Hospital | 1 | 0 | 1 | 2010 |
| AIDS Research Consortium of Atlanta | Academic/Hospital | 1 | 0 | 1 | 2010 |
| City of San Francisco | Government | 1 | 0 | 1 | 2012 |
| University of Massachusetts | Academic/Hospital | 1 | 0 | 1 | 2013 |
| University of Rochester | Academic/Hospital | 1 | 0 | 1 | 2012 |
8 organizations
Page 1 / 1